Accepted Articles
Back to the articles list |
Back to browse issues page
1- Clinical pharmacy department, Faculty of pharmacy, Deraya University, Minia, Egypt.
2- Internal Medicine and biomedical chemistry department, Egypt Ministry of Health and population. Minia, Egypt.
3- Neuropsychiatry department, Faculty of Medicine, Assiut University, Assiut, Egypt.
4- Pharmaceutics department, Faculty of Pharmacy, Minia University, Minia, Egypt.
2- Internal Medicine and biomedical chemistry department, Egypt Ministry of Health and population. Minia, Egypt.
3- Neuropsychiatry department, Faculty of Medicine, Assiut University, Assiut, Egypt.
4- Pharmaceutics department, Faculty of Pharmacy, Minia University, Minia, Egypt.
Abstract:
Background& Objectives: In this research, we investigated any possible effect of receiving Hyperbaric oxygen therapy (HBOT) or Risperidone on the autism core symptoms in children diagnosed as autism spectrum disorder (ASD).
Methods: A randomized, controlled clinical trial, in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, ages 5–8 years, divided into equal three groups, Group1 (G1): (N=60) received 40 sessions of (HBOT) within two months. Group2 (G2): (N=60) received Risperidone (0.25 mg daily for children under 20 kg; 0.5 mg daily for children equal to or over 20 kg) for six months. Group3 (G3): (N=60) control group received a placebo for six months. Assessment of their Childhood Autism Rating Scale (CARS) and Autism Treatment Evaluation Checklist (ATEC) scores was done at the beginning of the study (baseline) and after one year.
Results: The mean total CARS, total ATEC, and ATEC subscales scores were significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were in order (G1) then (G2) and finally (G3).
Interpretation & conclusions: There is a clear effect of using (HBOT) or Risperidone in treating the core symptoms of autism in children diagnosed as autism spectrum disorder. But using (HBOT) gives better results than using Risperidone therapy.
Methods: A randomized, controlled clinical trial, in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, ages 5–8 years, divided into equal three groups, Group1 (G1): (N=60) received 40 sessions of (HBOT) within two months. Group2 (G2): (N=60) received Risperidone (0.25 mg daily for children under 20 kg; 0.5 mg daily for children equal to or over 20 kg) for six months. Group3 (G3): (N=60) control group received a placebo for six months. Assessment of their Childhood Autism Rating Scale (CARS) and Autism Treatment Evaluation Checklist (ATEC) scores was done at the beginning of the study (baseline) and after one year.
Results: The mean total CARS, total ATEC, and ATEC subscales scores were significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were in order (G1) then (G2) and finally (G3).
Interpretation & conclusions: There is a clear effect of using (HBOT) or Risperidone in treating the core symptoms of autism in children diagnosed as autism spectrum disorder. But using (HBOT) gives better results than using Risperidone therapy.
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2020/12/14 | Accepted: 2021/02/13
Received: 2020/12/14 | Accepted: 2021/02/13
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Basic and Clinical Neuroscience Journal (BCN)
Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran, Iran.
Publisher Tel:
+9821 453 55 555; +9821 453 55 000 (EXT: 104)
URL: http://bcn.iums.ac.ir/
Publisher Email: info
nirp.ir
